No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance
Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated...
Saved in:
Published in | Journal of thrombosis and haemostasis Vol. 13; no. 4; pp. 592 - 600 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Limited
01.04.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary
Background
One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated.
Objectives
To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF.
Methods
Three type 3 von Willebrand disease (VWD) patients were infused with Haemate‐P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF‐deficient mice were injected with purified plasma‐derived human VWF obtained from donors with either blood group A, blood group B, or blood group O.
Results
In mice, we found no difference in clearance rate between plasma‐derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate‐P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two‐fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient.
Conclusion
There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non‐blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself. |
---|---|
AbstractList | One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated.BACKGROUNDOne of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated.To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF.OBJECTIVESTo determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF.Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O.METHODSThree type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O.In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient.RESULTSIn mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient.There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself.CONCLUSIONThere is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself. Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. Objectives To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Methods Three type 3 von Willebrand disease (VWD) patients were infused with Haemate‐P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF‐deficient mice were injected with purified plasma‐derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. Results In mice, we found no difference in clearance rate between plasma‐derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate‐P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two‐fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. Conclusion There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non‐blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself. Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. Objectives To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Methods Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. Results In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. Conclusion There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself. One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower plasma levels. The exact mechanism behind this relationship remains unknown, although effects on clearance have been postulated. To determine whether clearance of VWF is directly dependent on the presence of ABH antigens on VWF. Three type 3 von Willebrand disease (VWD) patients were infused with Haemate-P, and the relative loading of VWF with ABH antigens at different time points was measured. VWF-deficient mice were injected with purified plasma-derived human VWF obtained from donors with either blood group A, blood group B, or blood group O. In mice, we found no difference in clearance rate between plasma-derived blood group A, blood group B and blood group O VWF. Faster clearance of the blood group O VWF present in Haemate-P infused in type 3 VWD patients would have resulted in a relative increase in the loading of VWF with A and B antigens over time. However, we observed a two-fold decrease in the loading with A and B antigens in two out of three patients, and stable loading in the third patient. There is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that, in a direct comparison within one individual, blood group O VWF is not cleared faster than blood group A or blood group B VWF. Clearance differences between blood group O and non-blood group O individuals may therefore be related to the blood group status of the individual rather than the ABH antigen loading on VWF itself. |
Author | Dirven, R. J. Groeneveld, D. J. Cheung, K. L. Eikenboom, J. Bekkum, T. Castaman, G. Reitsma, P. H. Vlijmen, B. |
Author_xml | – sequence: 1 givenname: D. J. surname: Groeneveld fullname: Groeneveld, D. J. organization: Leiden University Medical Center – sequence: 2 givenname: T. surname: Bekkum fullname: Bekkum, T. organization: Leiden University Medical Center – sequence: 3 givenname: K. L. surname: Cheung fullname: Cheung, K. L. organization: Leiden University Medical Center – sequence: 4 givenname: R. J. surname: Dirven fullname: Dirven, R. J. organization: Leiden University Medical Center – sequence: 5 givenname: G. surname: Castaman fullname: Castaman, G. organization: Careggi University Hospital – sequence: 6 givenname: P. H. surname: Reitsma fullname: Reitsma, P. H. organization: Leiden University Medical Center – sequence: 7 givenname: B. surname: Vlijmen fullname: Vlijmen, B. organization: Leiden University Medical Center – sequence: 8 givenname: J. surname: Eikenboom fullname: Eikenboom, J. organization: Leiden University Medical Center |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25650553$$D View this record in MEDLINE/PubMed |
BookMark | eNp90UFPIyEUB3CycbNV14NfwJB4cPdQhaEww1GNu11j3EsTjxMKj0pDocJMjd9euq0eGl0uD5LfewH-B2gvxAAIHVNyTsu6mHeP57RqRP0F7VPOmmHdMLH3tpeMDdBBznNCqOQV-YYGFReccM720eo-Ylg5A0EDtjFhhY1LoDsM1q5LtHgVA35w3sM0qWCwVbqL6Szjy6sxnvoYDZ6l2C-xCp2bQci4-A97sPagylnDd_TVKp_haFsP0eTXzeR6PLz7-_vP9eXdULOmqYcVleV9vJGVAqG0HkkCnGltuTRgOKGGwVQbyyopa6gKgVpXbKStoaQR7BD92IxdpvjUQ-7ahcsavFcBYp9bKoQcjWrOm0JPd-g89imUy61VXYwQvKiTreqnCzDtMrmFSi_t24cW8HMDdIo5J7DvhJJ2HVZbwmr_hVXsxY7VrlOdi6FLyvn_dTw7Dy-fj25vJ-NNxyus56T1 |
CitedBy_id | crossref_primary_10_1161_JAHA_121_024581 crossref_primary_10_1182_bloodadvances_2021005928 crossref_primary_10_1111_bjh_15565 crossref_primary_10_1182_blood_2016_04_709436 crossref_primary_10_1016_j_jhep_2019_09_030 crossref_primary_10_1016_j_thromres_2020_11_016 crossref_primary_10_1111_jth_14304 crossref_primary_10_3233_BIR_15061 crossref_primary_10_1111_jth_13401 crossref_primary_10_12688_f1000research_13056_1 crossref_primary_10_1111_jth_14444 crossref_primary_10_1111_jth_14521 crossref_primary_10_1111_jth_13537 crossref_primary_10_1182_blood_2016_11_750885 crossref_primary_10_1182_blood_2020005843 crossref_primary_10_1111_jth_13294 |
Cites_doi | 10.1182/blood-2006-04-015065 10.1172/JCI26007 10.1146/annurev.biochem.67.1.395 10.1111/j.1538-7836.2006.02273.x 10.1182/blood.V69.6.1691.1691 10.1074/jbc.M010805200 10.1182/blood-2013-01-479527 10.1159/000054087 10.1182/blood-2005-02-0792 10.1074/jbc.M310436200 10.1111/j.1537-2995.2006.00975.x 10.1111/j.1538-7836.2003.00435.x 10.1172/JCI107471 10.1161/hq0202.103997 10.1046/j.1538-7836.2003.00359.x 10.1160/TH06-09-0549 10.1089/hum.2008.089 10.1055/s-0038-1665305 10.1111/j.1538-7836.2007.02588.x 10.1016/S0021-9258(19)50338-6 10.1172/JCI108846 10.1371/journal.ppat.1002942 10.1111/jth.12226 10.1182/blood-2012-09-455089 10.1182/blood.V88.5.1692.1692 10.1182/blood-2007-11-122945 10.1182/blood.V88.8.2951.bloodjournal8882951 10.1111/j.1538-7836.2009.03453.x |
ContentType | Journal Article |
Copyright | 2015 International Society on Thrombosis and Haemostasis 2015 International Society on Thrombosis and Haemostasis. Copyright © 2015 International Society on Thrombosis and Haemostasis |
Copyright_xml | – notice: 2015 International Society on Thrombosis and Haemostasis – notice: 2015 International Society on Thrombosis and Haemostasis. – notice: Copyright © 2015 International Society on Thrombosis and Haemostasis |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
DOI | 10.1111/jth.12867 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7836 |
EndPage | 600 |
ExternalDocumentID | 3640738681 25650553 10_1111_jth_12867 JTH12867 |
Genre | article Journal Article Comparative Study |
GroupedDBID | --- 05W 1OC 24P 29L 2WC 31~ 33P 36B 3SF 4.4 52U 52V 53G 5GY 5VS 66C 8-0 8-1 A00 AAESR AAEVG AAHHS AALRI AAONW AASGY AAXRX AAXUO AAZKR ABCUV ABDBF ABJNI ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADVLN ADXAS ADZMN AEEZP AEIMD AENEX AEQDE AFBPY AFEBI AFGKR AFJKZ AFPWT AFZJQ AHMBA AIACR AITUG AIURR AIWBW AJAOE AJBDE AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMRAJ AMYDB ATUGU AZBYB AZVAB BAWUL BHBCM BMXJE BOGZA BRXPI C45 CAG COF CS3 DCZOG DIK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBS EJD EMB EMK ESX F5P FDB FIJ FUBAC G-S GODZA HZ~ IHE IPNFZ IX1 KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES M41 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ ROL SUPJJ SV3 TEORI TR2 W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WVDHM WYJ ZZTAW AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AGCQF AIGII AKBMS AKYEP APXCP CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EFKBS EIF NPM 7T5 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3887-2191115892ae6acc490e53ccf59ded501d3ebcdf32997e26ace7c234cfd10863 |
IEDL.DBID | DR2 |
ISSN | 1538-7933 1538-7836 |
IngestDate | Fri Jul 11 10:12:57 EDT 2025 Wed Aug 13 10:32:24 EDT 2025 Mon Jul 21 05:51:40 EDT 2025 Tue Jul 01 00:27:09 EDT 2025 Thu Apr 24 23:00:06 EDT 2025 Wed Jan 22 16:24:33 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | von Willebrand disease ABO blood-group system blood group antigens von Willebrand factor type 3 VWD |
Language | English |
License | 2015 International Society on Thrombosis and Haemostasis. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3887-2191115892ae6acc490e53ccf59ded501d3ebcdf32997e26ace7c234cfd10863 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | http://www.jthjournal.org/article/S153878362208401X/pdf |
PMID | 25650553 |
PQID | 1667755665 |
PQPubID | 1086376 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1669447558 proquest_journals_1667755665 pubmed_primary_25650553 crossref_primary_10_1111_jth_12867 crossref_citationtrail_10_1111_jth_12867 wiley_primary_10_1111_jth_12867_JTH12867 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2015 2015-04-00 2015-Apr 20150401 |
PublicationDateYYYYMMDD | 2015-04-01 |
PublicationDate_xml | – month: 04 year: 2015 text: April 2015 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | Journal of thrombosis and haemostasis |
PublicationTitleAlternate | J Thromb Haemost |
PublicationYear | 2015 |
Publisher | Elsevier Limited |
Publisher_xml | – name: Elsevier Limited |
References | 1973; 52 1992; 267 2005; 115 2013; 122 1983; 50 2006; 4 2013; 121 2004; 2 2007; 97 1998; 67 1977; 60 2001; 276 1987; 69 2010; 21 2006; 108 2004; 279 2013; 11 2006; 46 2000; 37 2005; 106 2002; 22 2009; 7 2007; 5 2003; 1 2008; 111 1985; 37 2012; 8 1996; 88 Orstavik (10.1111/jth.12867_bb0030) 1985; 37 Borchiellini (10.1111/jth.12867_bb0025) 1996; 88 O'Donnell (10.1111/jth.12867_bb0075) 2000; 37 Wolofsky (10.1111/jth.12867_bb0120) 2012; 8 Nossent (10.1111/jth.12867_bb0065) 2006; 4 Mannucci (10.1111/jth.12867_bb0150) 2013; 122 Sadler (10.1111/jth.12867_bb0010) 1998; 67 Nachman (10.1111/jth.12867_bb0020) 1977; 60 Varadi (10.1111/jth.12867_bb0125) 2009; 7 Lenting (10.1111/jth.12867_bb0105) 2004; 279 Haberichter (10.1111/jth.12867_bb0090) 2006; 108 McCallum (10.1111/jth.12867_bb0040) 1983; 50 Gallinaro (10.1111/jth.12867_bb0085) 2008; 111 Fan (10.1111/jth.12867_bb0115) 2010; 21 Yamamoto (10.1111/jth.12867_bb0110) 2001; 276 Eikenboom (10.1111/jth.12867_bb0070) 2013; 121 Jaffe (10.1111/jth.12867_bb0015) 1973; 52 O'Donnell (10.1111/jth.12867_bb0050) 2005; 106 Lethagen (10.1111/jth.12867_bb0100) 2007; 5 Casari (10.1111/jth.12867_bb0145) 2013; 11 Gill (10.1111/jth.12867_bb0140) 1987; 69 Jenkins (10.1111/jth.12867_bb0045) 2006; 46 O'Donnell (10.1111/jth.12867_bb0055) 2002; 22 Tjernberg (10.1111/jth.12867_bb0095) 2004; 2 Matsui (10.1111/jth.12867_bb0035) 1992; 267 Morelli (10.1111/jth.12867_bb0060) 2007; 97 Motto (10.1111/jth.12867_bb0130) 2005; 115 Brown (10.1111/jth.12867_bb0080) 2003; 1 Stoddart (10.1111/jth.12867_bb0135) 1996; 88 |
References_xml | – volume: 111 start-page: 3540 year: 2008 end-page: 5 article-title: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor publication-title: Blood – volume: 2 start-page: 257 year: 2004 end-page: 65 article-title: Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues publication-title: J Thromb Haemost – volume: 60 start-page: 914 year: 1977 end-page: 21 article-title: Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes publication-title: J Clin Invest – volume: 67 start-page: 395 year: 1998 end-page: 424 article-title: Biochemistry and genetics of von Willebrand factor publication-title: Annu Rev Biochem – volume: 122 start-page: 648 year: 2013 end-page: 57 article-title: Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma‐free method: a prospective clinical trial publication-title: Blood – volume: 7 start-page: 1134 year: 2009 end-page: 42 article-title: Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor publication-title: J Thromb Haemost – volume: 11 start-page: 202 year: 2013 end-page: 11 article-title: Clearance of von Willebrand factor publication-title: J Thromb Haemost – volume: 88 start-page: 1692 year: 1996 end-page: 9 article-title: Clearance of normal and type 2A von Willebrand factor in the rat publication-title: Blood – volume: 276 start-page: 13701 year: 2001 end-page: 8 article-title: Murine equivalent of the human histo‐blood group ABO gene is ‐AB gene and encodes a glycosyltransferase with both A and B transferase activity publication-title: J Biol Chem – volume: 88 start-page: 2951 year: 1996 end-page: 8 article-title: Quantitative analysis of von Willebrand factor propeptide release effect of experimental endotoxemia and administration of 1‐deamino‐8‐D‐arginine vasopressin in humans publication-title: Blood – volume: 279 start-page: 12102 year: 2004 end-page: 9 article-title: An experimental model to study the survival of von Willebrand factor publication-title: J Biol Chem – volume: 46 start-page: 1836 year: 2006 end-page: 44 article-title: ABO blood group determines plasma von Willebrand factor levels: a biological function after all? publication-title: Transfusion – volume: 22 start-page: 335 year: 2002 end-page: 41 article-title: Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels publication-title: Arterioscler Thromb Vasc Biol – volume: 115 start-page: 2752 year: 2005 end-page: 61 article-title: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13‐deficient mice publication-title: J Clin Invest – volume: 106 start-page: 1988 year: 2005 end-page: 91 article-title: Bombay phenotype is associated with reduced plasma‐VWF levels and an increased susceptibility to ADAMTS13 proteolysis publication-title: Blood – volume: 37 start-page: 540 year: 2000 end-page: 7 article-title: Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens publication-title: J Vasc Res – volume: 21 start-page: 877 year: 2010 end-page: 90 article-title: Induction of human blood group A antigen expression on mouse cells, using lentiviral gene transduction publication-title: Hum Gene Ther – volume: 52 start-page: 2757 year: 1973 end-page: 64 article-title: Synthesis of antihemophilic factor antigen by cultured human endothelial cells publication-title: J Clin Invest – volume: 267 start-page: 8723 year: 1992 end-page: 31 article-title: Structures of the asparagine‐linked oligosaccharide chains of human von Willebrand factor publication-title: J Biol Chem – volume: 97 start-page: 534 year: 2007 end-page: 41 article-title: ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens publication-title: Thromb Haemost – volume: 69 start-page: 1691 year: 1987 end-page: 5 article-title: The effect of ABO blood group on the diagnosis of von Willebrand disease publication-title: Blood – volume: 37 start-page: 89 year: 1985 end-page: 101 article-title: Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level publication-title: Am J Hum Genet – volume: 50 start-page: 757 year: 1983 article-title: Factor VIII levels and blood group antigens publication-title: J Thromb Haemost – volume: 4 start-page: 2556 year: 2006 end-page: 62 article-title: von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis publication-title: J Thromb Haemost – volume: 1 start-page: 1714 year: 2003 end-page: 17 article-title: Increased clearance of von Willebrand factor antigen post‐DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? publication-title: J Thromb Haemost – volume: 108 start-page: 3344 year: 2006 end-page: 51 article-title: Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival publication-title: Blood – volume: 8 start-page: e1002942 year: 2012 article-title: ABO blood groups influence macrophage‐mediated phagocytosis of Plasmodium falciparum‐infected erythrocytes publication-title: PLoS Pathog – volume: 121 start-page: 2336 year: 2013 end-page: 9 article-title: VWF propeptide and ratios between VWF, VWF propeptide and FVIII in the characterization of type 1 von Willebrand disease publication-title: Blood – volume: 5 start-page: 1420 year: 2007 end-page: 30 article-title: von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery publication-title: J Thromb Haemost – volume: 108 start-page: 3344 year: 2006 ident: 10.1111/jth.12867_bb0090 article-title: Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival publication-title: Blood doi: 10.1182/blood-2006-04-015065 – volume: 115 start-page: 2752 year: 2005 ident: 10.1111/jth.12867_bb0130 article-title: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13‐deficient mice publication-title: J Clin Invest doi: 10.1172/JCI26007 – volume: 67 start-page: 395 year: 1998 ident: 10.1111/jth.12867_bb0010 article-title: Biochemistry and genetics of von Willebrand factor publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.67.1.395 – volume: 4 start-page: 2556 year: 2006 ident: 10.1111/jth.12867_bb0065 article-title: von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.02273.x – volume: 69 start-page: 1691 year: 1987 ident: 10.1111/jth.12867_bb0140 article-title: The effect of ABO blood group on the diagnosis of von Willebrand disease publication-title: Blood doi: 10.1182/blood.V69.6.1691.1691 – volume: 276 start-page: 13701 year: 2001 ident: 10.1111/jth.12867_bb0110 article-title: Murine equivalent of the human histo‐blood group ABO gene is acis‐AB gene and encodes a glycosyltransferase with both A and B transferase activity publication-title: J Biol Chem doi: 10.1074/jbc.M010805200 – volume: 122 start-page: 648 year: 2013 ident: 10.1111/jth.12867_bb0150 article-title: Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma‐free method: a prospective clinical trial publication-title: Blood doi: 10.1182/blood-2013-01-479527 – volume: 37 start-page: 540 year: 2000 ident: 10.1111/jth.12867_bb0075 article-title: Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens publication-title: J Vasc Res doi: 10.1159/000054087 – volume: 106 start-page: 1988 year: 2005 ident: 10.1111/jth.12867_bb0050 article-title: Bombay phenotype is associated with reduced plasma‐VWF levels and an increased susceptibility to ADAMTS13 proteolysis publication-title: Blood doi: 10.1182/blood-2005-02-0792 – volume: 279 start-page: 12102 year: 2004 ident: 10.1111/jth.12867_bb0105 article-title: An experimental model to study the in vivo survival of von Willebrand factor publication-title: J Biol Chem doi: 10.1074/jbc.M310436200 – volume: 46 start-page: 1836 year: 2006 ident: 10.1111/jth.12867_bb0045 article-title: ABO blood group determines plasma von Willebrand factor levels: a biological function after all? publication-title: Transfusion doi: 10.1111/j.1537-2995.2006.00975.x – volume: 2 start-page: 257 year: 2004 ident: 10.1111/jth.12867_bb0095 article-title: Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2003.00435.x – volume: 52 start-page: 2757 year: 1973 ident: 10.1111/jth.12867_bb0015 article-title: Synthesis of antihemophilic factor antigen by cultured human endothelial cells publication-title: J Clin Invest doi: 10.1172/JCI107471 – volume: 22 start-page: 335 year: 2002 ident: 10.1111/jth.12867_bb0055 article-title: Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/hq0202.103997 – volume: 1 start-page: 1714 year: 2003 ident: 10.1111/jth.12867_bb0080 article-title: Increased clearance of von Willebrand factor antigen post‐DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? publication-title: J Thromb Haemost doi: 10.1046/j.1538-7836.2003.00359.x – volume: 97 start-page: 534 year: 2007 ident: 10.1111/jth.12867_bb0060 article-title: ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens publication-title: Thromb Haemost doi: 10.1160/TH06-09-0549 – volume: 21 start-page: 877 year: 2010 ident: 10.1111/jth.12867_bb0115 article-title: Induction of human blood group A antigen expression on mouse cells, using lentiviral gene transduction publication-title: Hum Gene Ther doi: 10.1089/hum.2008.089 – volume: 37 start-page: 89 year: 1985 ident: 10.1111/jth.12867_bb0030 article-title: Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level publication-title: Am J Hum Genet – volume: 50 start-page: 757 year: 1983 ident: 10.1111/jth.12867_bb0040 article-title: Factor VIII levels and blood group antigens publication-title: J Thromb Haemost doi: 10.1055/s-0038-1665305 – volume: 5 start-page: 1420 year: 2007 ident: 10.1111/jth.12867_bb0100 article-title: von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2007.02588.x – volume: 267 start-page: 8723 year: 1992 ident: 10.1111/jth.12867_bb0035 article-title: Structures of the asparagine‐linked oligosaccharide chains of human von Willebrand factor publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)50338-6 – volume: 60 start-page: 914 year: 1977 ident: 10.1111/jth.12867_bb0020 article-title: Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes publication-title: J Clin Invest doi: 10.1172/JCI108846 – volume: 8 start-page: e1002942 year: 2012 ident: 10.1111/jth.12867_bb0120 article-title: ABO blood groups influence macrophage‐mediated phagocytosis of Plasmodium falciparum‐infected erythrocytes publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1002942 – volume: 11 start-page: 202 year: 2013 ident: 10.1111/jth.12867_bb0145 article-title: Clearance of von Willebrand factor publication-title: J Thromb Haemost doi: 10.1111/jth.12226 – volume: 121 start-page: 2336 year: 2013 ident: 10.1111/jth.12867_bb0070 article-title: VWF propeptide and ratios between VWF, VWF propeptide and FVIII in the characterization of type 1 von Willebrand disease publication-title: Blood doi: 10.1182/blood-2012-09-455089 – volume: 88 start-page: 1692 year: 1996 ident: 10.1111/jth.12867_bb0135 article-title: Clearance of normal and type 2A von Willebrand factor in the rat publication-title: Blood doi: 10.1182/blood.V88.5.1692.1692 – volume: 111 start-page: 3540 year: 2008 ident: 10.1111/jth.12867_bb0085 article-title: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor publication-title: Blood doi: 10.1182/blood-2007-11-122945 – volume: 88 start-page: 2951 year: 1996 ident: 10.1111/jth.12867_bb0025 article-title: Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1‐deamino‐8‐D‐arginine vasopressin in humans publication-title: Blood doi: 10.1182/blood.V88.8.2951.bloodjournal8882951 – volume: 7 start-page: 1134 year: 2009 ident: 10.1111/jth.12867_bb0125 article-title: Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2009.03453.x |
SSID | ssj0019520 |
Score | 2.2322142 |
Snippet | Summary
Background
One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O... One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower... Summary Background One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O... One of the major determinants of von Willebrand factor (VWF) plasma levels is ABO blood group status, and individuals with blood group O have ~ 25% lower... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 592 |
SubjectTerms | ABO Blood-Group System - blood ABO blood‐group system Animals Biomarkers - blood blood group antigens Drug Combinations Factor VIII - administration & dosage Female Humans Infusions, Intravenous Male Mice, Inbred C57BL Mice, Knockout Protein Binding Time Factors type 3 VWD von Willebrand disease von Willebrand Disease, Type 3 - blood von Willebrand Disease, Type 3 - diagnosis von Willebrand Disease, Type 3 - drug therapy von Willebrand factor von Willebrand Factor - administration & dosage von Willebrand Factor - genetics von Willebrand Factor - metabolism |
Title | No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjth.12867 https://www.ncbi.nlm.nih.gov/pubmed/25650553 https://www.proquest.com/docview/1667755665 https://www.proquest.com/docview/1669447558 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB1CDiGXNmn6sWlSpqWQXrysLUte0VNSGpZAcigbyCFgJFkm0GKXrDeH_PrOSLZp0hRKbwaPkGzNaJ40ozcAH72Z5Z7JB72ufZKreZpoK4okc2pmrbZpZfii8PmFWlzmZ1fyagM-D3dhIj_EeODGlhHWazZwY1e_G3l3M6XFVfFNcs7VYkD0baSOSrUMlIzBoEkHRc8qFLJ4hpYPfdEfAPMhXg0O5_Q5XA9DjXkm36frzk7d_SMWx__8lh141gNRPI6aswsbvnkBW-d9qH0P7i5a9H3JUSRkiwaj-8OYAoJtjXdtg3xgw8HnpsJYu-dohccnCwwZ8RgujSDNHpN-rpDkn2yDjqtXsAK-hOXp1-WXRdIXaUic4AWKVjz6BjnXmfHKOJfrmZfCuVrqyldyllbCW1fVgvxe4TMS8YXLRO7qios8iVew2bSNfwNoZZWTH6UNmnC5SY2urcqs4FiytKnSE_g0zFbpegJzrqPxoxw3Mt1NGX7jBD6Moj8ja8dTQgfDlJe94a7KVKmikIRx5QTej6_J5DiOYhrfroOMZp5EOZ_A66gqYy-EIAlTSkGDDRP-9-7Ls-UiPOz_u-hb2CbAJmPm0AFsdrdrf0igqLPvgvb_ArsoB2c |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VIgEXyldhocCAkOCS1SaOnbXUSwtUoXT3gBapFxTFjqNKoASx2R749czYSdRCkRC3SBnLTsYz82yP3wC8cuUsdUw-6HTtolTN40gbkUWJVTNjtImrki8KL5Yq_5wen8rTLdgf7sIEfohxw40tw_trNnDekL5o5d3ZlLyryq7Bda7ozcz57z6N5FGxlp6U0Zs0zULR8wr5PJ6h6eVo9AfEvIxYfcg52oEvw2BDpsnX6aYzU_vzNx7H__2aO3C7x6J4ECbPXdhyzT24sehP2-_D-bJF11cdRQK3WGKIgBiyQLCt8bxtkPds-Py5qTCU73m9xoPDHH1SPPp7I0gKZN7PNZL8lW3QcgELnoMPYHX0fvU2j_o6DZEV7KPI6dE3yLlOSqdKa1M9c1JYW0tduUrO4ko4Y6taUOjLXEIiLrOJSG1dcZ0nsQvbTdu4R4BGVimFUlqjCZuWcalroxIj-DhZmljpCbwZ1FXYnsOcS2l8K8a1THdW-N84gZej6PdA3HGV0N6g86K33XURK5VlkmCunMCL8TVZHR-llI1rN15GM1WinE_gYZgrYy8EIglWSkGD9Rr_e_fF8Sr3D4__XfQ53MxXi5Pi5MPy4xO4RfhNhkSiPdjufmzcU8JInXnmTeEXKRwLgw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qheJL_W6vrToVQV9yJNns5hafqvU4a3uInNAHIWQ_QqElKb1cH_zrO7ubBKsVxLdAZtlNZmfmt7uzvwF4Y8s4s4580MrKRpmYJJFULI9SLWKlpEpM6S4Kn8zF7Ht2dMpP1-B9fxcm8EMMG27OMry_dgZ-aapfjbw9G5NzFfk9uJ-JWLq6DYffBu6oRHLPyegtmiYh62iFfBpP3_R2MPoDYd4GrD7iTB_Cj36sIdHkfLxq1Vj__I3G8T8_5hFsdkgUD8LUeQxrtn4CGyfdWftTuJ43aLuao0jQFksM8Q9DDgg2FV43NbodG3f6XBsMxXveLvHgwwx9Sjz6WyNI6nOsn0sk-TvboHblK9wMfAaL6afFx1nUVWmINHMeilwefQOfyLS0otQ6k7HlTOuKS2MNjxPDrNKmYhT4cpuSiM11yjJdGVfliT2H9bqp7Tag4iajQEorNKazMillpUSqmDtM5ioRcgTvem0VumMwd4U0LophJdOeFf43juD1IHoZaDvuEtrrVV50lrssEiHynBPI5SPYH16TzbmDlLK2zcrLSEeUyCcj2ApTZeiFICSBSs5osF7hf---OFrM_MPOv4u-go2vh9Pi-PP8yy48IPDGQxbRHqy3Vyv7ggBSq156Q7gBAEcKMg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=No+evidence+for+a+direct+effect+of+von+Willebrand+factor%27s+ABH+blood+group+antigens+on+von+Willebrand+factor+clearance&rft.jtitle=Journal+of+thrombosis+and+haemostasis&rft.au=Groeneveld%2C+D.+J.&rft.au=Bekkum%2C+T.&rft.au=Cheung%2C+K.+L.&rft.au=Dirven%2C+R.+J.&rft.date=2015-04-01&rft.issn=1538-7933&rft.eissn=1538-7836&rft.volume=13&rft.issue=4&rft.spage=592&rft.epage=600&rft_id=info:doi/10.1111%2Fjth.12867&rft.externalDBID=10.1111%252Fjth.12867&rft.externalDocID=JTH12867 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7933&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7933&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7933&client=summon |